Examining neutrophil characteristics in lung cancer patients
Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer Undergoing Treatment
This study is testing whether certain types of white blood cells in lung cancer patients can help predict how well they will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT06244355 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the phenotypic, functional, and metabolomic characteristics of circulating neutrophil subpopulations in patients with metastatic non-small cell lung cancer (NSCLC). Blood samples will be collected from lung cancer patients before their first treatment and during their first evaluation visit, and compared to samples from healthy volunteers. The researchers hypothesize that distinct neutrophil subpopulations may play a role in tumor progression and resistance to immunotherapy, potentially serving as predictive biomarkers for treatment response.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of metastatic lung cancer who have not yet received treatment.
Not a fit: Patients with active infections, previous chemotherapy, or those who are pregnant or under guardianship may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that predict response to immunotherapy in lung cancer patients.
How similar studies have performed: While the role of neutrophil subpopulations in cancer is being explored, this specific approach to studying their characteristics in lung cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria common to lung cancer and COPD patients : * Age ≥ 18 years, * male or female, * affiliated with a Health Insurance, Inclusion Criteria for lung cancer patients : \- Diagnosis of metastatic stage lung cancer with mutation status, naïve treatment Inclusion Criteria for COPD patients : \- Diagnosis of COPD post-smoking Exclusion Criteria: * Tuberculosis or other acute or chronic bacterial infections * Chronic progressive viral infections (Hepatitis B and C, HIV) * Previous or ongoing chemotherapy * Impossibility of giving the subject informed information. * Opposition to the research. * Participation in another research study with an exclusion period still in progress at pre-inclusion (possible inclusion in an observational study) * Vulnerable individual (pregnant, parturient or breastfeeding woman), persons under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision) * Patients benefiting from the AME
Where this trial is running
Paris, Île-de-France Region
- Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital - Pneumology unit — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Principal investigator: Marie WISLEZ, Pr — Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
- Study coordinator: Marie WISLEZ, Pr
- Email: marie.wislez@aphp.fr
- Phone: +33 1 58 41 18 89
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.